In fast-aging Japan, struggles with dementia are a common story. But researchers hope that future breakthroughs will help them rewrite the ending. https://www.japantimes.co.jp/news/2025/09/17/japan/science-health/dementia-research/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #aging #elderly #mentalhealth #alzheimer039s #medicine #pharmaceuticals #dementia #lecanemab #donanemab
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals#eisai #health
Japan is expected to lower the price of lecanemab, an Alzheimer's drug, following a health ministry panel's report citing its low cost-effectiveness. https://www.japantimes.co.jp/news/2025/07/10/japan/science-health/lecanemab-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #lecanemab #alzheimer039s #medicine #health #dementia